85774-09-0

Basic information

• Product Name: METHYL D-HOMOALANINATE HCL
• Synonyms: METHYL D-HOMOALANINATE HCL;Methyl D-homoalaninate hydrochloride;Butanoic acid, 2-aMino-, Methyl ester, hydrochloride (1:1), (2R)-;D-alpha-Aminobutyric acid methyl ester hydrochloride;Methyl (R)-2-aminobutanoate hydrochloride;Butanoic acid, 2-aMino-, Methyl ester, hydrochloride , (2R)-;(R)-2-AMino-butyric acid Methyl ester;(R)-methyl 2-aminobutanoate hydrochloride
• CAS NO: 85774-09-0
• Molecular Formula: C₅H₁₁NO₂*ClH
• Molecular Weight: 153.61
• EINECS: 1533716-785-6
• Mol File: 85774-09-0.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: METHYL D-HOMOALANINATE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL D-HOMOALANINATE HCL(85774-09-0)
• EPA Substance Registry System: METHYL D-HOMOALANINATE HCL(85774-09-0)

Safety Data

• Hazardous Substances Data: 85774-09-0(Hazardous Substances Data)

Usage

Description

METHYL D-HOMOALANINATE HCL, also known as (R)-2-Aminobutanoic Acid Methyl Ester Hydrochloride, is an organic compound that serves as a key reagent in the synthesis of various pharmaceutical compounds. It is characterized by its ability to facilitate the production of pteridine derivatives and diazepanones, which have significant applications in the medical field.

Uses

Used in Pharmaceutical Industry:
METHYL D-HOMOALANINATE HCL is used as a reagent for the synthesis of pteridine derivatives, which possess antibacterial and antifungal activities. These derivatives are valuable in the development of new drugs to combat resistant infections and improve treatment options for various diseases.
METHYL D-HOMOALANINATE HCL is also used as a reagent in the synthesis of diazepanones, which act as dipeptidyl peptidase IV inhibitors. These inhibitors play a crucial role in the regulation of glucose levels in the body, making them potential candidates for the treatment of type 2 diabetes and other related metabolic disorders.

InChI:InChI=1/C5H11NO2.ClH/c1-3-4(6)5(7)8-2;/h4H,3,6H2,1-2H3;1H/t4-;/m1./s1

Upstream product

• 67-56-1 methanol 
• 2623-91-8 (R)-2-aminobutyric acid 
• 34306-42-8 Boc-Abu 
• 5959-29-5 S-(+)-2-amino-n-butyric acid hydrochloride 
• 861889-32-9 methyl 2-[(diphenylphosphoryl)amino]butanoate 
• 75266-41-0 (S)-2-amino-but-3-enoic acid methyl ester hydrochloride 
• 1492-24-6 L-2-aminobutyric acid 

Downstream Products

• 947586-41-6 methyl (2R)-2-(propan-2-ylamino)butanoate hydrochloride 
• 755039-52-2 (R)-methyl 2-(cyclopentylamino)butanoate 
• 1408282-65-4 Methyl (R)-N-(4-methoxyphenylsulfonyl)aminobutanoate 
• 3828-69-1 N-(N-Benzyoxycarbonyl-L-threonyl)-D-2-amino-buttersaeure-methylester 
• 767570-56-9 D-Abu-NMe 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors

Protein kinase inhibitors and epigenetic regulatory molecules are two main kinds of anticancer drugs developed in recent years. Both kinds of drugs harbor their own advantages and disadvantages in the treatment of cancer, and the development of small mole

Preparation method of (S)-(+)-2-aminobutanamide hydrochloride

The invention discloses a preparation method of (S)-(+)-2-aminobutanamide hydrochloride, and relates to a preparation method of a levetiracetam key intermediate, and the method comprises the followingspecific steps: carrying out esterification reaction on L-2-aminobutyric acid serving as a starting material and thionyl chloride, and concentrating part of solvent after the reaction is finished; introducing ammonia gas to neutralize generated hydrogen chloride and residual thionyl chloride; and filtering, introducing ammonia gas, and carrying out an ammonolysis reaction to obtain the (S)-2-aminobutanamide hydrochloride after the treating is finished. According to the preparation method, the starting material is simple and easy to obtain, the one-pot method is adopted, the atom utilization rate is high, operation is easy and convenient, and the obtained product quality is high.